Shots:

• The P-III (U-EXCEED) induction study evaluates upadacitinib (45mg, qd) vs PBO in adults with mod, to sev. CD who had inadequately responded to or were intolerant of biological therapy
• The trial meet both 1EPs of clinical remission & endoscopic response @12wks., a greater proportion of patients achieved steroid-free clinical remission & endoscopic response @12wks. safety results were consistent with the known profile of upadacitinib & no new safety risks were observed
• Additionally, similar results were seen with clinical remission per SF/AP (40% vs 14%), improvement in intestinal mucosa by endoscopy, improvement in early symptom @2wks. along with clinical remission @4wks.

 Ref: AbbVie | Image: abbvie